ConductScience.org, home

Trial · NCT00889837

Staccato Loxapine Pulmonary Safety in Patients With COPD

NCT00889837, Phase 1, Completed, Alexza Pharmaceuticals, Inc.

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Staccato Loxapine Pulmonary Safety in Patients With COPD. Trials, record NCT00889837. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00889837

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Staccato Loxapine Pulmonary Safety in Patients With COPD
NCT number
NCT00889837
Status
Completed
Phases
Phase 1
Enrollment
53 participants, actual
Lead sponsor
Alexza Pharmaceuticals, Inc.
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled Loxapine, Inhaled Placebo
First posted
2009-04-29
Last updated
2017-03-14

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChange in FEV1 from baseline by spirometryat each post-treatment time point (15 min to 34 hr)
SecondaryChange in FVC from baseline by spirometryat each post-treatment time point (15 min to 34 hr)
SecondaryTreatment emergent adverse eventsPost-treatment time points

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMIDListed as
24745666BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00889837

GET https://conductscience.org/api/trials/v1/NCT00889837/registered